Key result
The 2018 ERS International Congress highlighted advances in pulmonary vascular disease, including risk stratification, molecular mechanisms, right ventricle function, and acute pulmonary embolus.
Why the study?
To summarise high-quality pulmonary vascular disease studies presented at the 2018 ERS International Congress across four key subject areas.
This article summarizes high-quality studies on pulmonary vascular disease presented at the 2018 ERS International Congress.
May guide current pulmonary vascular disease management; leaves open prospective validation of highlighted mechanisms and RV advances.
The 2018 European Respiratory Society (ERS) International Congress in Paris, France, highlighted the subject of pulmonary vascular disease (PVD). 2018 was an exciting year for the PVD community as it was the first ERS International Congress since the formation of Assembly 13, which is dedicated to PVD, pulmonary embolism and the right ventricle. This article aims to summarise the high-quality studies presented at the 2018 Congress into four subject areas: the use of risk stratification in pulmonary arterial hypertension, the molecular mechanisms and treatment of pulmonary hypertension (PH), understanding and improving the right ventricle in PH, and finally, advances in the field of acute pulmonary embolus.
No takes yet. Share an insight, caveat, or question.
Ramjug et al. (2019) conducted a review in Pulmonary vascular disease. The 2018 ERS International Congress highlighted advances in pulmonary vascular disease, including risk stratification, molecular mechanisms, right ventricle function, and acute pulmonary embolus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: